Higher rates of serious infection, herpes zoster, and neutropenia were observed with upadacitinib compared to MTX, especially in the 30 mg group; higher rates of CPK elevation was also observed with both upadacitinib doses but without clinical consequences. This evidence concerns the gene PIK3C2A and neutropenia.